CLOSING THE DIAGNOSTIC GAP IN OVARIAN CANCER DETECTION
With
Associate Professor Michelle Hill
Founder and CEO
ProSeek bio
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Brisbane & Sydney | May 2026
After 15 years in academia, Associate Professor Michelle Hill founded ProSeek bio to address one of the most urgent challenges in women’s health: closing the diagnostic gap in ovarian cancer.
For too long, women suspected of ovarian cancer have faced an impossible choice — undergo invasive surgery for diagnosis, only for up to 80% of those procedures to reveal no cancer, or delay intervention and risk diagnosis at a later stage when treatment options are fewer and survival outcomes are significantly worse.
ProSeek bio is developing a non-invasive blood test designed to help clinicians determine whether surgery is truly necessary. Using advanced glycoproteomics to detect ovarian cancer biomarkers in blood, the technology is being developed to deliver more precise diagnostic insights through blood sample processed in existing pathology laboratories.
The goal is clear: enable earlier diagnosis, reduce unnecessary surgeries, lower healthcare costs and improve survival outcomes for women.
Ovarian cancer remains the most lethal women’s cancer because symptoms are often vague, common and easily overlooked. Bloating, pelvic pain and unexplained weight changes are frequently dismissed, contributing to delayed diagnosis in more than 70% of cases. Yet when ovarian cancer is detected early, more than 90% of women survive at least five years. When diagnosed late, survival drops dramatically.
ProSeek bio was founded to change that reality.
Built on more than a decade of biomarker research, the company is translating academic discovery into a clinical diagnostic tool with the potential to transform how ovarian cancer is detected and managed.
By giving clinicians a faster, safer and less invasive way to assess risk, Assoc Prof Hilll talks about how ProSeek bio is working to change the diagnostic pathway for ovarian cancer — reducing harm, improving decision-making and helping save women’s lives.
Source: Adapted from transcript
Event Credit: Medical Technology Association of Australia (MTAA)
Ovarian cancer statistics credit: Ovarian Cancer Research Foundation (OCRF)
-
Generosity of spirit in teaching
The Ramaciotti Medal for Excellence is considered one of the most prestigious awards in biomedical research in Australia and is highly sought after by researchers in the field.
In 2022, Professor Matthew Kiernan was the recipient of the Ramaciotti Medal for Excellence and the associated $50,000 award.
Australian Health Journal spoke with Professor Kiernan to hear about his journey in medicine and science to try and uncover and understand diseases and his generosity of spirit to pass on what he has learnt.
-
Cardiologist broadens Tasmania’s surgical abilities
Dr Heath Adams is a Tasmanian born, bred and educated interventional and structural cardiologist who works at Hobart Private and Royal Hobart Hospital and is a researcher through the Menzies Research Institute.
Dr Adams clinical interest and expertise is in the management of aortic stenosis, valvular heart disease and acute coronary syndromes. Dr Adams performs coronary interventions including stenting, and structural heart interventions including TAVI, mitral edge to edge repair, mitral valve replacement and left atrial appendage closure. In 2020, Heath performed the first TAVI in Tasmania, is the clinical lead for the local program at the Royal Hobart Hospital and is a nationally accredited TAVI practitioner.
-
WA and QLD RSV Immunisation programs show drops in infant hospitalisations
RSV is the number one cause of hospitalisation of Australian children under five years of age, according to the Immunisation Foundation of Australia (IFA). There are mounting concerns that Australians at greatest risk of severe Respiratory Syncytial Virus, or RSV will miss out on protection against the lung infection, with the Federal Government failing to commit to a national RSV immunisation program.
